ADVANCEMENTS AND FUTURE PERSPECTIVES OF 1, 2, 3 TRIAZOLE SCAFFOLD AS PROMISING ANTIVIRAL AGENT IN DRUG DISCOVERY
AbstractSevere viral infections like Covid-19 are emerging now a day and are the common causes of human illness and death. Presently, we have a limited availability of antiviral chemotherapeutic agents to prevent and treat these infections, so it is the need of an hour to develop potential antiviral drugs against various harmful and fatal viral infections. A large quantity of research has been performed on 1,2,3 triazole and their derivatives, which has proved the promising antiviral activity of this heterocyclic nucleus. Among nitrogen-containing heterocyclic compounds, 1, 2, 3-triazoles are privileged structure motifs and received great attention in academics and industry. Even though absent in nature, 1, 2, 3-triazoles have found broad applications in drug discovery, organic synthesis, polymer chemistry, supramolecular chemistry, bioconjugation, chemical biology, fluorescent imaging, and materials science. 1, 2, 3 triazole nucleus is one of the most important and well-known heterocycle which is a common and integral skeleton of a variety of medicinal compounds like antidepressant, antihistaminic, antioxidant, antitubercular, anti-Parkinson, antineoplastic, antihypertensive, antimalarial, local anaesthetic, antianxiety, antiobesity and immunomodulatory agents, etc. 1, 2, 3 triazole emerged as a pharmacologically significant scaffolds due to its broad and potent activity against severe infections. This review primarily lays emphasis on the recent advancements in the synthesis and biological evaluation of 1, 2, 3 triazole derivatives as antiviral agents which may facilitate the development of more potent and effective antiviral agents.
Article Information
2
4805-4818
1009 KB
496
English
IJPSR
Pavan Kumar D. Chopade * and Anwar Rafique Shaikh
M. C. E. Society's Allana College of Pharmacy, Azam Campus, Camp, Pune, Maharashtra, India.
pavya111@gmail.com
22 March 2022
24 May 2022
09 June 2022
10.13040/IJPSR.0975-8232.13(12).4805-18
01 December 2022